NEW YORK – June 2, 2026 – The Cardiovascular Research Foundation ® (CRF ® ) announced the highly anticipated lineup of late-breaking research to be presented at New York Valves: The Structural Heart Summit TM . The premier educational meeting for the structural heart community will take place June 24-26, 2026, at the Jacob K. Javits Convention Center, North in New York, NY.
This year’s program will feature 22 late-breaking clinical science and 8 late-breaking innovation presentations that are poised to transform the treatment of structural heart disease. The research will reveal the latest breakthroughs in transcatheter aortic valve replacement (TAVR) and introduce next-generation innovations for mitral and tricuspid valve therapies. These findings are expected to immediately impact clinical practice, helping to refine patient selection, optimize techniques, and define the standard of care for new and emerging treatments.
Now in its third year, New York Valves is the world’s foremost educational forum for interventionalists, surgeons, and clinical cardiologists dedicated to the field of structural heart disease.
Wednesday, June 24, 2026
Late-Breaking Clinical Science: TAVR Session I
10:15 AM — 11:45 AM EDT
7-Year Valve Durability in the PARTNER 3 Trial
Philippe Pibarot
Seven-Year TAVR Outcomes in Low-Risk Patients treated with Balloon-Expandable Valves in the United States
Sreekanth Vemulapalli
Outcomes of TAVR with the Evolut Platform: Results from the VA-CART Program
Neel Butala
8-Year Durability and Reintervention with the Evolut Valve: Single-Center Results
Sachin S. Goel
6-Year Outcomes from the Evolut TAVR Low-Risk Bicuspid Study
Basel Ramlawi
TAVR for Asymptomatic Severe AS: Updated Results from the EARLY-TAVR trial
Philippe Genereux
Late-Breaking Clinical Science: Tricuspid
1:45 PM — 2:45 PM EDT
Transcatheter Tricuspid Valve Replacmement after Failed T-TEER: The REDEMPTION registry
Prasham Dave
Treatment Pathways and Outcomes in TRISCEND-Ineligible Patients: A Single-Center Study
Ashtyn N. Williams
Thirty-day Outcomes After T-TEER with the TriClip System: Early Experience from the TVT Registry
Wayne Batchelor
Valve Thrombosis after TTVR: The TRIPLACE Registry
Julio Echarte Morales
Thursday, June 25, 2026
Late-Breaking Clinical Science: Mitral
One-Year Outcomes of M3 TMVR in Patients with Mitral Annular Calcification: The ENCIRCLE-MAC
Mayra Guerrero
LAMPOON Trends and Outcomes: Insights from the STS/ACC TVT Registry
Jaffar M. Khan
One-Year Outcomes of PASCAL M-TEER: Real-World Evidence from the TVT Registry
Azeem Latib
Repeat M-TEER in the TVT Registry: Temporal Trends, Predictors, and Outcomes
John Thomas Saxon
Real-World Evaluation of MitraClip vs. PASCAL for M-TEER
Pier Pasquale Leone
M-TEERr for Patients With a Small Mitral Valve Orifice Area: The REPAIR Study
Philipp von Stein
Late-Breaking Innovation I
AI-Enabled ECG analysis for Detection and Prediction of Structural Heart Disease
Hak Seung Lee
EVolution Of heart vaLVe teams and the patient Experience (EVOLVE): A Multicenter, Mixed Methods Study of TAVR Programs Across the United States
Dhaval Kolte
Real-World Outcomes of the Shortcut Device for Leaflet Modification Prior to ViV TAVR
Raj R. Makkar
BASILICA Trends and Outcomes: Insights from the STS/ACC TVT Registry
Friday, June 26, 2026
Late-Breaking Clinical Science: TAVR Session II
Baseline Clinical and Echocardiographic Characteristics among Moderate AS Patients Enrolled in the PROGRESS Trial
Measuring Quality in the Evaluation, Surveillance, and Treatment of Aortic Stenosis: First Large-Scale Report from the AHA Target AS Initiative
Brian R. Lindman
A Prospective Multicenter Study of an EHR-Facilitated Valve Care Pathway for Severe Aortic Stenosis: The DETECT AS II Study
Sammy Elmariah
Real-World Outcomes of TAVR with the NAVITOR valve for Patients with Small Aortic Annuli: Results from the STS/ACC Registry
Raviteja Reddy Guddeti
A Randomized Trial Comparing Femoral or Radial Secondary Access in TAVR
Antony Walton
New Permanent Pacemaker Implantation After TAVR for Pure Aortic Regurgitation: Results from the ALIGN-AR Study
James M. McCabe
Late-Breaking Innovation II
Pulsed Field Ablation of the LAA Prior to LAA Closure: A Novel Approach to Reduce Peri-Device Leak
Vivek Y. Reddy
M-TEER vs. Valve-In-Ring in Patients with Failed Surgical Mitral Valve Repair: Insights from the REDO-MR Registry
Guido Ascione
Six-Month Outcomes of Mitral Valve Lithotripsy using the SMARTCRACK Balloon for Mitral Stenosis with Severe Mitral Annular or Valvular Calcification: The SMART-MAC trial
Kent Chak-yu So
TAVR with the JenaValve Trilogy System in Patients with Continous-Flow LVADS: The JENA-VAD NOW Registry
Ravi Ramana
In addition to late-breaking research, New York Valves will feature:
HOW TO REGISTER:
Media may apply for press registration by emailing jromero@crf.org .
About CRF ®
The Cardiovascular Research Foundation ® (CRF ® ) is a global leader in interventional cardiovascular medicine, driving innovation, spearheading groundbreaking research, and transforming education in the field. Through its relentless pursuit of excellence, CRF not only accelerates medical breakthroughs but also equips healthcare professionals with the tools and knowledge necessary to enhance survival rates and elevate the quality of life for millions worldwide. CRF’s centers of excellence include the CRF Skirball Center for Innovation, CRF Clinical Trials Center, CRF Center for Education, CRF Digital, TCTMD®, and Structural Heart: The Journal of the Heart Team .
For more information, visit www.crf.org .
###